Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status. Abbott's Healthy Food Rx community-focused "food is medicine" program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes. CHICAGO, June 20, 2025 /PRNewswire/ -- Late-

肿瘤标志物（tumor marker，TM）很多，但每个指标什么意义，适用于什么肿瘤？笔者对其进行了总结，希望对大家有所帮助。一、常见、通用的肿瘤血清 TM1、癌胚抗原（CEA）CEA升高常见于大肠癌、胰腺癌、胃癌、乳腺癌、甲状腺髓样癌、肝癌、肺癌、卵巢癌、泌尿系肿瘤等。但吸烟、妊娠期和心血管疾病、糖尿病、肠道憩室炎、直肠息肉、结肠炎、胰腺炎、肝硬化、肝炎、肺部疾病等，15%～53%的患者血清CEA也会升高，所以CEA不是恶性肿瘤的特异性标志，在诊断上只有辅助价值。大量临床实践证实，术前或治疗前CEA浓度能明确预示肿瘤的状态、存活期及有无手术指征等。术前CEA浓度越低，说明病期越早，肿瘤转移、复发的可能越小，其生存时间越长；反之，术前CEA浓度越高说明病期较晚，难于切除，预后差。CEA检测还可对经手术或其他方法治疗使CEA恢复正常的病人，进行长期随访，监测其复发和转移。通常采用以下方案：术后第六周一次；术后三年内，每月一次；3～5年每三月一次；5～7年每半年一次；7年后一年一次。若发现升高，两周后再测一次，两次都升高则提示复发和转移。正常参考值≤5ng/mL2、癌抗原125（CA125

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。在医保控费持续深化与药品集采常态化的双重压力下，中国医药产业正经历深度结构性调整期。当大多数企业都在思考“如何活下去”时，我们看到，恒瑞和瀚森通过差异化转型成功实现逆势增长。这两家企业在长期实践中，通过持续创新的战略布局和卓越的经营管理能力，以扎实的业绩成果确立了国内创新药行业领先地位，为国内企业转型升级提供了可借鉴的标杆案例。值得注意的是，作为"夫妻店"模式的两家企业，二者在发展战略上呈现出"和而不同"的特点——既存在诸多共性特征，又保持各自独特的差异化路径。接下来，我们将基于他们2024年度的财报数据进行对比分析。1、2024年经营业绩对比（1）收入结构恒瑞医药分行业营业收入总营收占比毛利率医药制造业250.10亿元89.37%85.06%*抗肿瘤145.87亿元52.12%92.57%*代谢和心血管17.48亿元6.25%76.61%*免疫和呼吸系统7.77亿元2.78%83.69%*神经科学42.89亿元15.33%84.76%*造影

ARLINGTON, Va., June 20, 2025 /PRNewswire/ -- New survey data from 408 global scientists and researchers reveals a rapid increase in AI adoption—alongside mounting hesitation around trust, training, and usability. As budgets tighten and workflow efficiency becomes more critical, scientists are both accelerating the use of AI and raising red flags about its limitations. The latest findings from BioInformatics' Beyond the Bench series uncover how academic, government, and industry researchers are

HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: ) has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking

Bengaluru: The European Union's medicines regulator on Friday granted a conditional authorisation for Madrigal Pharmaceuticals ' drug for a type of fatty liver disease, paving the way to make it the first treatment available for the condition in the region. The drug, sold as Rezdiffra , was first approved in the United States in March last year. The disease known as non-alcoholic steatohepatitis (NASH), or more recently renamed as metabolic dysfunction-associated steatohepatitis (MASH), causes e

Surgeons at Baylor St. Luke's Medical Center successfully performed a fully robotic heart transplant on an adult patient – the first reported in the United States. Using a surgical robot, lead surgeon Dr. Kenneth Liao and his team made small, precise incisions, eliminating the need to open the chest and break the breast bone. Liao removed the diseased heart, and the new heart was implanted through preperitoneal space, avoiding chest incision. "Opening the chest and spreading the breastbone can a

Symposium previews new content for Standards of Care in Overweight and Obesity, designed to improve patient care and outcomes CHICAGO, June 20, 2025 /PRNewswire/ -- Recent developments for the new Standards of Care in Overweight and Obesity guidelines, the first clinical guidance of its kind, were presented during the Standards of Care in Overweight and Obesity 2025 Updates symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. The Obesity Association

Results highlight A1C improvements, reduced reliance on medications, and strong patient engagement through personalized, root-cause-based care CHICAGO, June 20, 2025 /PRNewswire/ -- L-Nutra Health, the medical division of nutrition technology leader L-Nutra, presented compelling real-world data today at the American Diabetes Association's 85th Scientific Sessions, reinforcing the success of lifestyle medicine in reversing the course of type 2 diabetes. The data reflects the outcomes of a compreh

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for